NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Andrew, This is from Linda Powers ASM 6/29/2024 transcript. Sawston has the capacity to handle up to potentially 15K patients/year.

Just before we leave that subject, in terms of capacity, our current anticipation, and this is based on assessments by the advent folks who are the experts, is that we anticipate that each of the grade C labs should be able to, with two shifts operating, produce about 1,000 or 1,100 patients' products per year per grade C lab. We anticipate, we're so fortunate this building is very large and it's about close to 88,000 square feet on two floors. We anticipate, ultimately, when the building is fully built out, if it's fully built out with C labs, with our current understanding, and the engineers don't change things, we anticipate being able to, up to potentially 15,000 patients a year with all grade C labs in the rest of the building.

So you can start to see, even if we get part of the way towards 15,000 a year, that is an enormous amount of patients, especially for personalized cell therapies. My understanding is, for example, the big companies who bought the CAR T cell technologies in their first years of commercial operations made 50 patients' products. Having the eventual capacity to make up to 15,000 patients would be absolutely enormous.

We also have been doing a lot of preparations of the nuts and bolts of things that would be needed for commercial operations. I won't take time on that, but just to give you one glimpse of it, again, giving you flavor, we have established an existing today. We have controlled clinical-grade cryo storage for three million vials of doses. So three million is a pretty good amount to start with.